J Bacteriol 1997, 179:2557–2566.PubMed 6. Sieradzki 7-Cl-O-Nec1 ic50 K, Tomasz A: Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus -type resistance, cell concentration dependence of the MIC, and

antibiotic tolerance in vancomycin-susceptible S. aureus . Antimicrob Agents Chemother 2006, 50:527–533.PubMedCrossRef 7. Utaida S, Pfeltz RF, Jayaswal RK, Wilkinson BJ: Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2006, 50:1541–1545.PubMedCrossRef 8. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K: Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus see more aureus Mu50. Antimicrob Agents Chemother 2000, 44:2276–2285.PubMedCrossRef 9. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML: Reduced vancomycin susceptibility in Staphylococcus aureus , including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010, 23:99–139.PubMedCrossRef 10. Cui L, Lian JQ, Neoh HM, Reyes E, Hiramatsu K: DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus . Antimicrob Agents Chemother 2005, 49:3404–3413.PubMedCrossRef 11. Kuroda M, Kuwahara-Arai K, Hiramatsu

K: Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization

method. Biochem Biophys Res Commun 2000, 269:485–490.PubMedCrossRef 12. Mongodin E, Finan J, Climo MW, Rosato A, Gill S, Archer GL: Microarray transcription Niclosamide analysis of clinical Staphylococcus aureus isolates resistant to vancomycin. J Bacteriol 2003, 185:4638–4643.PubMedCrossRef 13. Cui L, Neoh HM, Shoji M, Hiramatsu K: Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus . Antimicrob Agents Chemother 2009, 53:1231–1234.PubMedCrossRef 14. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF: Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 2011, 7:e1002359.PubMedCrossRef 15. BVD-523 research buy Doddangoudar VC, Boost MV, Tsang DN, O’Donoghue MM: Tracking changes in the vraSR and graSR two component regulatory systems during the development and loss of vancomycin non-susceptibility in a clinical isolate. Clin Microbiol Infect 2011, 17:1268–1272.PubMedCrossRef 16. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM: Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog 2012, 8:e1002505.PubMedCrossRef 17.